BRVEBraveheart Bio
Clinical-stage biopharma developing oral small-molecule cardiac myosin inhibitors for hypertrophic cardiomyopathy (HCM).
$18IPO price
$383MRaised
$29.8Day-1 close
12.22%Day-1 return
Clinical-stage biopharma developing oral small-molecule cardiac myosin inhibitors for hypertrophic cardiomyopathy (HCM).
Company description (source: StockAnalysis)
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
51CFO read: CFO must master clinical-stage financial modeling, FDA development pathway capital planning, and biopharma capital efficiency.
Management details per the SEC prospectus.
Does your company need this kind of CFO?
51CFO matches you with Western CFOs who have each run a full US IPO — plus other C-level talent. First shortlist within 48 hours; free 30-minute listing-readiness read.
Talk to us